This research presents the first extensive mutational study of N-terminal amino acids necessary for activity of a bacterial Zeta class glutathione transferase (GST). Our studies on UG30 tetrachlorohydroquinone reductive dehalogenase (PcpC) revealed that, similar to other Zeta class GSTs, N-terminal Ser and Cys residues play critical roles in glutathione binding and their mutation results in functional and structural changes to PcpC. Mutation of the N-terminal Ser and Cys residues decreased the apparent temperature optimum (by 6-10 degrees C) and maximum (by 5 degrees C) of PcpC. Also, mutation of Ser12 and Ser15 resulted in structural changes that were accompanied by the emergence of substrate inhibition. Mutation of the N-terminal Cys residue adversely affected the rate of the enzymatic reaction, but not on the metabolites formed. This study adds to the knowledge that, despite low sequence homology for the Zeta GST protein family, differences in preferred electrophilic substrates, and the manner in which glutathione is utilized in catalysis, GSTs from prokaryotic and eukaryotic organisms rely upon the same critical amino acids for glutathione binding.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.resmic.2009.07.010DOI Listing

Publication Analysis

Top Keywords

mutational study
8
n-terminal amino
8
tetrachlorohydroquinone reductive
8
reductive dehalogenase
8
amino acids
8
zeta class
8
n-terminal ser
8
ser cys
8
cys residues
8
glutathione binding
8

Similar Publications

Background: Oxidative stress is strongly linked to neurodegeneration through the activation of c-Abl kinase, which arrests α-synuclein proteolysis by interacting with parkin interacting substrate (PARIS) and aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2). This activation, triggered by ataxia-telangiectasia mutated (ATM) kinase, leads to dopaminergic neuron loss and α-synuclein aggregation, a critical pathophysiological aspect of Parkinson's disease (PD). To halt PD progression, pharmacological inhibition of c-Abl kinase is essential.

View Article and Find Full Text PDF

Objectives: This study aimed to comprehensively investigate the molecular landscape of gastric cancer (GC) by integrating various bioinformatics tools and experimental validations.

Methodology: GSE79973 dataset, limma package, STRING, UALCAN, GEPIA, OncoDB, cBioPortal, DAVID, TISIDB, Gene Set Cancer Analysis (GSCA), tissue samples, RT-qPCR, and cell proliferation assay were employed in this study.

Results: Analysis of the GSE79973 dataset identified 300 differentially expressed genes (DEGs), from which COL1A1, COL1A2, CHN1, and FN1 emerged as pivotal hub genes using protein-protein interaction network analysis.

View Article and Find Full Text PDF

Aims: This study aims to identify and evaluate promising therapeutic proteins and compounds for breast cancer treatment through a comprehensive database search and molecular docking analysis.

Background: Breast cancer (BC), primarily originating from the terminal ductal-lobular unit of the breast, is the most prevalent form of cancer globally. In 2020, an estimated 2.

View Article and Find Full Text PDF

Bioinformatics Analysis Reveals Microrchidia Family Genes as the Prognostic and Therapeutic Markers for Colorectal Cancer.

Endocr Metab Immune Disord Drug Targets

January 2025

Department of Laboratory Medicine, Taizhou First People's Hospital, Huangyan Hospital of Wenzhou Medical University, Taizhou, Zhejiang, China.

Aim: The aim of this study is to examine the role of the microrchidia (MORC) family, a group of chromatin remodeling proteins, as the therapeutic and prognostic markers for colorectal cancer (CRC).

Background: MORC protein family genes are a highly conserved nucleoprotein superfamily whose members share a common domain but have distinct biological functions. Previous studies have analyzed the roles of MORCs as epigenetic regulators and chromatin remodulators; however, the involvement of MORCs in the development and pathogenesis of CRC was less examined.

View Article and Find Full Text PDF

Rhabdomyosarcoma (RMS) is a family of phenotypically myogenic paediatric cancers consisting of two major subtypes: fusion-positive (FP) RMS, most commonly involving the PAX3::FOXO1 fusion gene, formed by the fusion of paired box 3 (PAX3) and forkhead box O1 (FOXO1) genes, and fusion-negative (FN) RMS, lacking these gene fusions. In humans, DNA methylation patterns distinguish these two subtypes as well as mutation-associated subsets within these subtypes. To investigate the biological factors responsible for these methylation differences, we profiled DNA methylation in RMS tumours derived from genetically engineered mouse models (GEMMs) in which various driver mutations were introduced into different myogenic lineages.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!